Yet Another Claim About the Benefits of Antidepressants Bites The Dust
Former FDA officials write that claims that the black warning led to an increase in youth are "factually inaccurate in ways that are directly verifiable."
Depression Drug Approved by FDA Had 11 Failed Trials and an Advisory Committee Vote...
Rejected by the FDA four times; an advisory committee vote against approval. Yet in 2023, gepirone (Exxua) was approved for depression.
Anthropology, Arctic Iceland and Antidepressant Withdrawal: A Conversation With Fiona Frenzen
Fiona Frenzen joins us to talk of her experiences of healing from antidepressant withdrawal and how moving to Iceland had a powerful effect on her health and wellbeing.
Visual Snow Syndrome: Can SSRIs Literally Change How You See the World?
SSRI antidepressants have been linked to a number of adverse effects. A recent study presents evidence that a new condition may need to be...
Medication-Free Treatment in Norway Found Effective Over the Short Term
Those who received drug-tapering support did just as well or better than those receiving treatment as usual.
Commentary: Does First Year Treatment With an Antipsychotic Lead to Long-Term Harm?
There is no good evidence that antipsychotics provide a benefit to first-episode or early-episode psychotic patients.
New Evidence in Support of Tapering Protocols for First-Episode Psychosis
The study shows that tapering can be successfully and relatively safely done by most people after first-episode psychosis.
Not Even the Unborn Are Safe from Psychiatric Harm
Medical organizations and the media dismiss the experts and the large body of research telling of fetal harm from exposure to SSRIs during pregnancy.
Antipsychotics Do Not Provide a Clinically Meaningful Benefit Over the Short-Term: A Review of...
70 years of RCTs fail to provide evidence that antipsychotics provide a clinically meaningful benefit for treating acute psychotic episodes.
Exploding Myths About Schizophrenia: An Interview with Courtenay Harding
The Vermont Longitudinal Study, led by Courtenay Harding, belied conventional beliefs about schizophrenia by showing remarkably good outcomes for patients discharged in the 1950s and '60s.
“Dad, Something’s Not Right. I Need Help”: Richard Fee on the Dangers of Adderall
In appointments that last five to seven minutes, all doctors do is push drugs—psychiatric drugs, ADHD meds, everything.
Summing up the STAR*D Scandal: The Public was Betrayed, Millions were Harmed, and the...
American psychiatry, the NIMH, the larger medical community, and mainstream media have betrayed the American public by failing to make this scandal known.
The New York Times Is Now Engulfed in the STAR*D Scandal
The New York Times published yet again the fraudulent result from the STAR*D trial. Will the mainstream media ever tell of this scandal?
Winding Back the Clock: What If the STAR*D Investigators Had Told the Truth?
The STAR*D Study has been cited as real-world evidence of the efficacy of antidepressants. In truth, it told of a failed paradigm of care.
The STAR*D Scandal: Scientific Misconduct on a Grand Scale
The American Journal of Psychiatry Needs to Retract Study That Reported Fraudulent Results
Screening for Perinatal Depression: An Effective Intervention, or One That Does More Harm Than Good?
Why does the U.S. describe perinatal screening as providing a proven benefit, while the task forces in the U.K. and Canada see no evidence of such benefit?
Our RCT Fetish: How the “Gold Standard” for Research Has Led to A Societal...
After Joanna Moncrieff and colleagues published their study debunking the low-serotonin theory of depression, the editor of Mad in Sweden, Lasse Mattila, wrote Sweden’s...
Thomas Insel Makes A Case for Abolishing Psychiatry
In his new book, former NIMH director Thomas Insel, while exploring the causes of poor mental health outcomes in the United States, omits any mention of NIMH studies that tell of how the drugs worsen long-term outcomes.
Medicating Preschoolers for ADHD: How “Evidence-Based” Psychiatry Has Led to a Tragic End
The prescribing of stimulants to preschoolers diagnosed with ADHD is on the rise, which is said to be an "evidence-based" practice. A review of that "evidence base" reveals that claims that ADHD is characterized by genetic and brain abnormalities are belied by the data, and that the NIMH trial of methylphenidate in this age group told of long-term harm.
Michael Hengartner – Evidence-biased Antidepressant Prescription
We talk with Dr. Michael Hengartner about his new book which addresses the overprescribing of antidepressant drugs and critically examines the scientific evidence on their efficacy and safety.
The Visual Illusion of Efficacy in Psychiatric Drug Trials
Published reports of clinical trials of psychiatric drugs typically include a graphic showing the efficacy of the study drug in reducing symptoms of the...
Anatomy of an Industry: Commerce, Payments to Psychiatrists and Betrayal of the Public Good
Pharmaceutical companies paid psychiatrists $340 million from 2014 through 2020, corrupting every aspect of the testing and marketing of new psychiatric drugs.
A Short History of Tardive Dyskinesia: 65 Years of Drug-Induced Brain Damage That Rolls...
Psychiatry has long turned a blind eye to the full scope of harm associated with TD. New TD drugs "work" by further impairing brain function.
The Latest “Breakthrough Therapy”: Expensive New Drugs for Tardive Dyskinesia
The increased prescribing of antipsychotics, which frequently cause a brain injury that manifests as tardive dyskinesia, has provided pharmaceutical companies with a lucrative new market opportunity.
An FDA Whistleblower’s Documents: Commerce, Corruption, and Death
In 2008, a reviewer of psychiatric drugs at the FDA, Ron Kavanagh, complained to Congress that the FDA was approving a new antipsychotic that was ineffective and yet had adverse effects that increased the risk of death. Twelve years later, a review of the whistleblower documents reveal an FDA approval process that can lead to the marketing of drugs sure to harm public health.
